MedTrace Logo

Detection of COVID-19 Decompensation

NCT04575532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-09-13

No results posted yet for this study

Summary

In this study we will be monitoring for patient events (emergency department admission, hospital admission, admission to an observation unit, or death) and evaluating the feasibility and utility of using pinpointIQ in the management of patients with COVID-19. Vital sign (physiology data) is collected to build a Covid Decompensation Index and contribute data to a Covid Digital Hub supported by the National Institutes of Health.

Conditions

  • Covid19

Interventions

DEVICE

Use of the pinpointIQ solution (physIQ, Inc.)

Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Illinois at Chicago

    collaborator OTHER

  • physIQ, Inc.

    lead INDUSTRY

Principal Investigators

  • Karen Larimer, PhD · physIQ, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-09-09
Completion
2021-09-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575532 on ClinicalTrials.gov